Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780770 | 0.82 | LIPE (0.39) | KMT2ARAB9AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL30466779 | 0.81 | LIPE (0.39) | KMT2ARAB9AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL2453019 | 0.81 | LPL (0.36) | LIPEAAK1ALPL | |
| SCHEMBL25282736 | 0.81 | LIPE (0.39) | KMT2ARAB9AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL3670014 | 0.79 | ALPL (0.36) | AAK1ALPL | |
| SCHEMBL30132973 | 0.79 | ALPL (0.36) | AAK1ALPL | |
| SCHEMBL30006214 | 0.78 | EGFR (0.38) | SMN1; SMN2LIPEAAK1LMNAALPL | |
| SCHEMBL14038064 | 0.78 | EGFR (0.38) | SMN1; SMN2LIPEAAK1LMNAALPL | |
| SCHEMBL23658807 | 0.75 | UCHL1 (0.40) | AAK1ALPL | |
| SCHEMBL16046359 | 0.74 | AAK1 (0.44) | AAK1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090661-B1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | GRUENENTHAL GMBH (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220372041-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | KMT2A 3656/4885RAB9A 2448/4885MEN1 1270/4885 |
| US-20220372041-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | KMT2A 3656/4885RAB9A 2448/4885MEN1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.